Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1143808 | 0.79 | XIAP (0.42) | ALOX15PTPN2PTPN1CDC25B | |
| SCHEMBL1143729 | 0.76 | ALOX15 (0.36) | ALOX15PTPN2PTPN1CDC25B | |
| SCHEMBL1143784 | 0.74 | TAAR1 (0.37) | ALOX15PTPN2PTPN1CDC25BHSD17B10 | |
| SCHEMBL1143807 | 0.74 | SULT1E1 (0.36) | ALOX15PTPN2PTPN1CDC25BHSD17B10 | |
| SCHEMBL1143512 | 0.73 | USP2 (0.38) | ALOX15PTPN2PTPN1CDC25B | |
| SCHEMBL1143641 | 0.73 | CYP1A2 (0.46) | ALOX15HSD17B10 | |
| SCHEMBL22579081 | 0.72 | PTPN1 (0.42) | ALOX15PTPN2PTPN1CDC25B | |
| SCHEMBL1143889 | 0.71 | CYP1A2 (0.40) | ALOX15PTPN2PTPN1CDC25BHSD17B10 | |
| SCHEMBL1143891 | 0.71 | ALOX15 (0.36) | ALOX15PTPN2PTPN1CDC25B | |
| SCHEMBL1143321 | 0.70 | XIAP (0.41) | ALOX15PTPN2PTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486435-B2 | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | claimed |
| US-20150297551-A1 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2015-10-22 | — | — | US | claimed |
| US-8952071-B2 | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | claimed |
| US-20110046219-A1 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS, INC | 2011-02-24 | — | — | US | claimed |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | BIOJIVA LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12156860-B2 | Disorders implicating PUFA oxidation | BIOJIVA LLC (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | BIOJIVA LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | BIOJIVA LLC | 2022-09-29 | — | — | US | disclosed |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | BIOJIVA LLC | 2022-05-05 | — | — | US | disclosed |
| US-11285125-B2 | Oxidative retinal diseases | RETROTOPE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | RETROTOPE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2012148930-A2 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148929-A2 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148926-A2 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148927-A2 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20110046219-A1 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS, INC | 2011-02-24 | — | — | US | disclosed |
| EP-2237664-A1 | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | Edison Pharmaceuticals, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009089224-A1 | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | KCNQ2 4597/4885ALOX15 9/4885LOXL2 505/4885 |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | CPT1B, PSEN2, NLN | KCNQ2 4597/4885ALOX15 9/4885LOXL2 505/4885 |
| US-12156860-B2 | Disorders implicating PUFA oxidation | GPX4, CPT1A, FABP1 | KCNQ2 2810/4885ALOX15 9/4885LOXL2 119/4885 |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | KCNQ2 4276/4885ALOX15 19/4885LOXL2 359/4885 |
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | KCNQ2 4276/4885ALOX15 19/4885LOXL2 359/4885 |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | KCNQ2 2810/4885ALOX15 9/4885LOXL2 119/4885 |
| US-20150297551-A1 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, ECHS1, NDUFS6 | KCNQ2 658/4885ALOX15 232/4885LOXL2 955/4885 |
| US-11285125-B2 | Oxidative retinal diseases | ALDH1A2, TXNRD2, STARD3 | KCNQ2 4276/4885ALOX15 19/4885LOXL2 359/4885 |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | CPT1B, PSEN2, NLN | KCNQ2 4597/4885ALOX15 9/4885LOXL2 505/4885 |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | ACADM, CPT1A, ALDH2 | KCNQ2 3276/4885ALOX15 43/4885LOXL2 560/4885 |
| US-20110046219-A1 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, ECHS1, NDUFS6 | KCNQ2 658/4885ALOX15 232/4885LOXL2 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.